For Media Inquiries:
The Pacific Business Group on Health has serious concerns with the price that Gilead has announced for remdesivir, a drug that reduces COVID-19 patients’ recovery time. Read the statement here.
Most major employers are embracing social distancing and other measures to safely bring employees back to work amid the new normal imposed by COVID-19, a recent Pacific Business Group on Health poll showed. See the results here.
The Coronavirus Aid, Relief, and Economic Security Act (S. 3548; H.R. 748), passed by Congress and signed into law today, is a very important step in the right direction at addressing the immediate needs of businesses and individuals. In this policy statement, PBGH calls on Congress and the Administration as it develops the next anticipated COVID-19 package to include the following provisions.
In a letter to Health and Human Services Secretary Alex Azar, the Pacific Business Group on Health calls on the Trump administration to address the urgent need to protect and strengthen independent primary care practices during the COVID-19 pandemic.
The Pacific Business Group on Health, as part of a coalition of physicians, consumer and business leaders, is calling on California state legislators to protect the very foundation of our health care system by supporting independent primary care providers vulnerable to the huge economic impacts of the COVID-19 pandemic.
Pacific Business Group on Health (PBGH) is pleased to announce Shawn Gremminger as Director, Health Policy beginning on March 16, 2020.
Employers’ Prescription for Affordable Drugs (EmployersRx) has announced its support of H.R. 5304, the “PBM Transparency and Prescription Drug Costs Act.” This bipartisan legislation will markedly lower private health insurance premiums and increase competition in the marketplace, according to a July 2019 report from the Congressional Budget Office.
Chairman Doggett, Ranking Member Nunes, and members of the House Ways and Means Health Subcommittee, thank you for the opportunity to provide a written statement for today’s hearing on behalf of the Employers’ Prescription for Affordable Drugs (EmployersRx), a coalition of employers united in advocacy to drive down the cost of prescription drugs—one of the biggest challenges in health care.
Tired of being “the sucker at the table,” a group representing Fortune 500 companies has formed a lobby to push congressional drug-pricing policies that focus beyond Medicare. Employers’ Prescription for Affordable Drugs has described its goal as “to mobilize large employers to drive down prescription drug costs by advocating for public policies based on increased competition, transparency and value.”
Legislation aiming to reduce drug prices has thus far focused on changes to federal programs such as Medicare. But Walmart, Pepsi, and other large companies provide employer-sponsored health insurance to more than 150 million Americans, making them the largest footers of health bills.